- $94.97m
- $65.85m
- 29
- 54
- 59
- 44
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.56 | ||
| Price to Tang. Book | 0.56 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -28.76% | ||
| Return on Equity | -37.51% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.14 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. The Company’s subsidiary, Axion Bio, Inc., in-licensed certain bispecific antibodies, including AXN-2510/IMM2510 and AXN-27M/IMM27M, a monoclonal antibody targeting cytotoxic T-lymphocyte associated antigen 4, or CTLA-4. AXN-2510/IMM2510, the lead in-licensed product candidate, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumor cancers. AXN-27M/IMM27M is an antibody-dependent cellular cytotoxicity-enhanced monoclonal antibody targeting CTLA-4, which has been designed to promote intratumoral regulatory T cell depletion to enhance the efficacy and reduce the toxicity associated with first-generation anti-CTLA-4 antibodies.
Directors
- Bronson Crouch CHM (48)
- Sandeep Laumas CFO (53)
- Vijay Chiruvolu CTO (59)
- Zachary Roberts OTH (43)
- Neil Gibson LED (65)
- Gwendolyn Binder-Scholl IND (46)
- George Matcham IND (68)
- R. Kent McGaughy IND (49)
- Jack Nielsen IND (57)
- Margo Roberts IND
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 31st, 2018
- Public Since
- March 19th, 2021
- No. of Shareholders
- 13
- No. of Employees
- 14
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 6,558,927
- Address
- 3963 Maple Avenue, Suite 350, DALLAS, 75219
- Web
- https://instilbio.com/
- Phone
- +1 9724993350
- Auditors
- Deloitte & Touche LLP
Upcoming Events for TIL
Instil Bio Inc Annual Shareholders Meeting
Instil Bio Inc Annual Shareholders Meeting
Q2 2025 Instil Bio Inc Earnings Release
Similar to TIL
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Instil Bio share price?
As of Today at 21:20 UTC, shares in Instil Bio are trading at $14.48. This share price information is delayed by 15 minutes.
How has the Instil Bio share price performed this year?
Shares in Instil Bio last closed at $14.48 and the price had moved by +29.06% over the past 365 days. In terms of relative price strength the Instil Bio share price has outperformed the S&P500 Index by +16.37% over the past year.
What are the analyst and broker recommendations for Instil Bio?
The overall consensus recommendation for Instil Bio is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Instil Bio dividend yield?
Instil Bio does not currently pay a dividend.
Does Instil Bio pay a dividend?
Instil Bio does not currently pay a dividend.
When does Instil Bio next pay dividends?
Instil Bio does not currently pay a dividend.
How do I buy Instil Bio shares?
To buy shares in Instil Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Instil Bio?
As of the previous close price of $14.48, shares in Instil Bio had a market capitalisation of $94.97m.
Where are Instil Bio shares listed?
Here are the trading details for Instil Bio:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: TIL
What kind of share is Instil Bio?
Based on an overall assessment of its quality, value and momentum Instil Bio is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Instil Bio share price forecast for 2025?
The analyst consensus target price for shares in Instil Bio is $113.67. That is 685.01% above the last closing price of $14.48.
Analysts covering Instil Bio currently have a consensus Earnings Per Share (EPS) forecast of -$11.23 for the next financial year.
Find out moreWhat is the trend in the Instil Bio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Instil Bio. Over the past six months, its share price has underperformed the S&P500 Index by -49.46%.
As of the last closing price of $14.48, shares in Instil Bio were trading -41.32% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Instil Bio PE Ratio?
The Instil Bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $14.48.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Instil Bio?
Instil Bio's management team is headed by:
- Bronson Crouch - CHM
- Sandeep Laumas - CFO
- Vijay Chiruvolu - CTO
- Zachary Roberts - OTH
- Neil Gibson - LED
- Gwendolyn Binder-Scholl - IND
- George Matcham - IND
- R. Kent McGaughy - IND
- Jack Nielsen - IND
- Margo Roberts - IND